Literature DB >> 16236048

Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients.

Ylva Böttiger1, Christina Brattström, Lars Bäckman, Kerstin Claesson, James T Burke.   

Abstract

AIMS: The influence of the trimethoprim-sulphamethoxazole combination on the steady-state pharmacokinetics of sirolimus, a potent macrocyclic immunosuppressant, was studied in renal transplant recipients.
METHODS: Fifteen kidney transplant recipients were treated with sirolimus 8-23 mg m(-2) in combination with azathioprine and prednisolone from the day of transplantation. Whole blood sirolimus AUC and C(max) were determined on days 6 and 7 after transplantation. On day 7, sirolimus was coadministered with the first dose of trimethoprim (80 mg) and sulphamethoxazole (400 mg).
RESULTS: On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1). Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1). The mean difference in the dose-corrected AUC((0-24 h)) was 0.40% (-9.4, +10).
CONCLUSIONS: A single dose of trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236048      PMCID: PMC1884939          DOI: 10.1111/j.1365-2125.2005.02475.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.

Authors:  Y Böttiger; J Säwe; C Brattström; J Tollemar; J T Burke; G Häss; J J Zimmerman
Journal:  Clin Pharmacol Ther       Date:  2001-01       Impact factor: 6.875

2.  Sirolimus and erythromycin interaction: two cases.

Authors:  K Claesson; C Brattström; J T Burke
Journal:  Transplant Proc       Date:  2001-05       Impact factor: 1.066

3.  Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

Authors:  C G Groth; L Bäckman; J M Morales; R Calne; H Kreis; P Lang; J L Touraine; K Claesson; J M Campistol; D Durand; L Wramner; C Brattström; B Charpentier
Journal:  Transplantation       Date:  1999-04-15       Impact factor: 4.939

4.  Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia.

Authors:  G Ferrazzini; J Klein; H Sulh; D Chung; E Griesbrecht; G Koren
Journal:  J Pediatr       Date:  1990-11       Impact factor: 4.406

5.  Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection.

Authors:  D W Holt; T Lee; A Johnston
Journal:  Clin Ther       Date:  2000       Impact factor: 3.393

6.  A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine.

Authors:  D G Maki; B C Fox; J Kuntz; H W Sollinger; F O Belzer
Journal:  J Lab Clin Med       Date:  1992-01

7.  Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.

Authors:  B D Kahan; K L Napoli; P A Kelly; J Podbielski; I Hussein; D L Urbauer; S H Katz; C T Van Buren
Journal:  Clin Transplant       Date:  2000-04       Impact factor: 2.863

Review 8.  Pharmacokinetics and metabolism of sirolimus.

Authors:  H L Gallant-Haidner; D J Trepanier; D G Freitag; R W Yatscoff
Journal:  Ther Drug Monit       Date:  2000-02       Impact factor: 3.681

9.  Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.

Authors:  Xia Wen; Jun-Sheng Wang; Janne T Backman; Jouko Laitila; Pertti J Neuvonen
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

10.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.

Authors:  M Sattler; F P Guengerich; C H Yun; U Christians; K F Sewing
Journal:  Drug Metab Dispos       Date:  1992 Sep-Oct       Impact factor: 3.922

View more
  4 in total

1.  Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.

Authors:  Hideaki Kagaya; Masatomo Miura; Takenori Niioka; Mitsuru Saito; Kazuyuki Numakura; Tomonori Habuchi; Shigeru Satoh
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

2.  Recurrent urinary tract infections in kidney transplant recipients.

Authors:  Subhashis Mitra; George John Alangaden
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

3.  Urinary tract infections in renal transplant recipients.

Authors:  George Alangaden
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

4.  Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology.

Authors:  Amelia-Naomi Sabo; Sarah Jannier; Guillaume Becker; Jean-Marc Lessinger; Natacha Entz-Werlé; Véronique Kemmel
Journal:  Pharmaceutics       Date:  2021-03-30       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.